Insider Trading disclosures for eFFECTOR Therapeutics Inc

The latest disclosure was made by Caroline M. Loewy in eFFECTOR Therapeutics Inc where a trade of 800 Stock Option (Right to Buy) done was reported to US exchanges on June 13, 2024.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Show

Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Caroline M. Loewy	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Jun 2024	800	800	-		-	Stock Option (Right to Buy)
Barbara Klencke	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Jun 2024	800	800	-		-	Stock Option (Right to Buy)
Brian M. Gallagher	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Jun 2024	800	800	-		-	Stock Option (Right to Buy)
Elizabeth P. Bhatt	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Jun 2024	800	800	-		-	Stock Option (Right to Buy)
Kristen Harrington-Smith	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Jun 2024	800	800	-		-	Stock Option (Right to Buy)
Stephen T. Worland	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 1.68 per share.	15 May 2024	1,806	12,494	-	1.7	3,039	Common Stock
Michael Byrnes	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 1.68 per share.	15 May 2024	1,387	3,117	-	1.7	2,334	Common Stock
Gallagher M. Brian	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	19 Feb 2024	2,000	2,000	-		-	Stock Option (Right to Buy)
Bhatt Elizabeth	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	19 Feb 2024	2,000	2,000	-		-	Stock Option (Right to Buy)
J. Douglas Warner	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	19 Feb 2024	25,000	25,000	-		-	Stock Option (Right to Buy)
Harrington-Smith Kristen	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	19 Feb 2024	2,000	2,000	-		-	Stock Option (Right to Buy)
M. Loewy Caroline	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	19 Feb 2024	2,000	2,000	-		-	Stock Option (Right to Buy)
Byrnes Michael	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	19 Feb 2024	40,000	40,000	-		-	Stock Option (Right to Buy)
Klencke Barbara	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	19 Feb 2024	2,000	2,000	-		-	Stock Option (Right to Buy)
T. Worland Stephen	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	19 Feb 2024	80,000	80,000	-		-	Stock Option (Right to Buy)
Stephen T. Worland	Director, Chief Executive Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	11 Aug 2023	33,799	0	-		-	Stock Option (Right to Buy)
Stephen T. Worland	Director, Chief Executive Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.52 per share.	11 Aug 2023	33,799	261,225	-	0.5	17,575	Common Stock
John W. Smither	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	22 Jun 2023	20,000	20,000	-		-	Stock Option (Right to Buy)
Barbara Klencke	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	22 Jun 2023	20,000	20,000	-		-	Stock Option (Right to Buy)
Brian M. Gallagher	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	22 Jun 2023	20,000	20,000	-		-	Stock Option (Right to Buy)
Elizabeth Bhatt	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	22 Jun 2023	20,000	20,000	-		-	Stock Option (Right to Buy)
Kristen Harrington-Smith	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	22 Jun 2023	20,000	20,000	-		-	Stock Option (Right to Buy)
Stephen T. Worland	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.46 per share.	15 May 2023	6,401	227,426	-	0.5	2,938	Common Stock
Michael Byrnes	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.46 per share.	15 May 2023	4,863	38,747	-	0.5	2,232	Common Stock
John W. Smither	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	20 Jan 2023	36,875	36,875	-		-	Stock Option (Right to Buy)
Barbara Klencke	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	20 Jan 2023	28,125	28,125	-		-	Stock Option (Right to Buy)
Brian M. Gallagher	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	20 Jan 2023	50,938	50,938	-		-	Stock Option (Right to Buy)
Elizabeth Bhatt	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	20 Jan 2023	30,000	30,000	-		-	Stock Option (Right to Buy)
Kristen Harrington-Smith	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	20 Jan 2023	28,125	28,125	-		-	Stock Option (Right to Buy)
Stephen T. Worland	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 Jan 2023	1,000,000	1,000,000	-		-	Stock Option (Right to Buy)
Michael Byrnes	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 Jan 2023	500,000	500,000	-		-	Stock Option (Right to Buy)
Douglas J. Warner	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 Jan 2023	250,000	250,000	-		-	Stock Option (Right to Buy)
Stephen T. Worland	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.47 per share.	15 Nov 2022	6,047	221,025	-	0.5	2,832	Common Stock
Michael Byrnes	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.47 per share.	15 Nov 2022	4,651	33,884	-	0.5	2,179	Common Stock
Douglas J. Warner	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	08 Aug 2022	618,160	618,160	-		-	Stock Option (Right to Buy)
Brian M. Gallagher	Director	Purchase of securities on an exchange or from another person at price $ 1.59 per share.	23 Jun 2022	30,000	30,000	-	1.6	47,700	Common Stock
Stephen T. Worland	Director, President and Chief Executive	Grant, award, or other acquisition of securities at price $ 0.00 per share.	20 Jun 2022	520,674	520,674	-		-	Stock Option (Right to Buy)
Michael Byrnes	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	20 Jun 2022	235,541	235,541	-		-	Stock Option (Right to Buy)
Alana B. McNulty	Chief Business Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	20 Jun 2022	150,000	150,000	-		-	Stock Option (Right to Buy)
John W. Smither	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Jun 2022	20,000	20,000	-		-	Stock Option (Right to Buy)
Barbara Klencke	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Jun 2022	20,000	20,000	-		-	Stock Option (Right to Buy)
Brian M. Gallagher	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Jun 2022	20,000	20,000	-		-	Stock Option (Right to Buy)
Elizabeth Bhatt	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Jun 2022	20,000	20,000	-		-	Stock Option (Right to Buy)
Kristen Harrington-Smith	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Jun 2022	13,333	13,333	-		-	Stock Option (Right to Buy)
Stephen T. Worland	Director, President and Chief Executive	Purchase of securities on an exchange or from another person at price $ 1.37 per share.	07 Jun 2022	20,000	214,978	-	1.4	27,400	Common Stock
Michael Byrnes	Chief Financial Officer	Purchase of securities on an exchange or from another person at price $ 1.33 per share.	07 Jun 2022	25,000	29,233	-	1.3	33,263	Common Stock
Stephen T. Worland	Director, President and Chief Executive	Grant, award, or other acquisition of securities at price $ 1.53 per share.	13 May 2022	1,837	194,978	-	1.5	2,811	Common Stock
Michael Byrnes	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 1.53 per share.	13 May 2022	4,233	4,233	-	1.5	6,476	Common Stock
Kristen Harrington-Smith	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Feb 2022	40,000	40,000	-		-	Stock Option (Right to Buy)
Stephen T. Worland	Director, President and Chief Executive	Grant, award, or other acquisition of securities at price $ 0.00 per share.	20 Jan 2022	520,674	520,674	-		-	Stock Option (Right to Buy)

Showing 1 to 50 of 130 entries

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades disclosures

Insider Trading disclosures for eFFECTOR Therapeutics Inc

The latest disclosure was made by Caroline M. Loewy in eFFECTOR Therapeutics Inc where a trade of 800 Stock Option (Right to Buy) done was reported to US exchanges on June 13, 2024.

Screeners based on Insider Trading and SAST parameters